Madrigal Pharmaceuticals, INC

Madrigal Pharmaceuticals announced robust second-quarter 2026 financial results, driven by a 71% year-over-year increase in Rezdiffra net sales to $364.3 million, with over 49,000 patients on the treatment.

Madrigal Pharmaceuticals stockholders approved the 2026 Stock Plan and 2026 Employee Stock Purchase Plan at the annual meeting, alongside a new Nonqualified Deferred Compensation Plan.

Madrigal Pharmaceuticals announced robust first-quarter 2026 financial results, driven by significant growth in Rezdiffra net sales and strategic pipeline expansion.

Madrigal Pharmaceuticals announced a reclassification of its Board of Directors to ensure a more equal distribution of members across its three classes.

Madrigal Pharmaceuticals announced robust fourth-quarter and full-year 2025 financial results, driven by nearly $1 billion in Rezdiffra sales and significant pipeline expansion.

Madrigal Pharmaceuticals has amended its agreement with Roche, gaining exclusive control over patent term extensions for its drug Rezdiffra in exchange for a delayed royalty reduction.

Madrigal Pharmaceuticals reports significant revenue increase driven by Rezdiffra sales, alongside substantial investments in pipeline expansion and commercialization efforts.

Madrigal Pharmaceuticals reported a significant increase in Rezdiffra net product revenue for Q1 2026, alongside substantial investments in pipeline expansion through new licensing agreements.

Madrigal Pharmaceuticals, Inc. announced significant revenue growth for Rezdiffra, its MASH treatment, following FDA and EC approvals, while also expanding its pipeline with a new GLP-1 receptor agonist.

Madrigal Pharmaceuticals reports significant revenue growth for Rezdiffra, advances European market entry, and expands its pipeline with a new GLP-1 asset.

Madrigal Pharmaceuticals reports $137.25 million in net product revenue for Q1 2025 following the FDA approval and commercial launch of Rezdiffra for MASH.

Madrigal Pharmaceuticals reported its first product revenue of $62.2 million in the third quarter of 2024, following the commercial launch of Rezdiffra in April.

Madrigal Pharmaceuticals achieved significant product revenue of $958.4 million in 2025 from its MASH drug Rezdiffra, while expanding its pipeline with new therapeutic candidates.

Madrigal Pharmaceuticals highlights a transformational year marked by Rezdiffra's FDA approval, a successful public offering, and strategic expansion into Europe.

Madrigal Pharmaceuticals' 10-K filing details the company's financial status and progress in developing resmetirom for NASH treatment, including FDA review and clinical trial results.

William John Sibold, President and CEO and a Director of Madrigal Pharmaceuticals, Inc., sold 2,500 shares of common stock on July 17, 2026.

Rebecca Taub, a Director at Madrigal Pharmaceuticals, was granted restricted stock units and stock options on June 17, 2026.

Richard S. Levy, a Director at Madrigal Pharmaceuticals, Inc., was granted restricted stock units and stock options on June 17, 2026.

Jacqualyn A. Fouse, a Director at Madrigal Pharmaceuticals, Inc., acquired 454 shares of common stock and was granted stock options for 766 shares.

Madrigal Pharmaceuticals Director James M. Daly was granted restricted stock units and stock options on June 17, 2026, as detailed in a Form 4 filing.

Madrigal Pharmaceuticals director Daniel J. Brennan was granted restricted stock units and a stock option, according to a Form 4 filing.

Madrigal Pharmaceuticals will hold its annual stockholders meeting on June 20, 2025, to vote on director re-elections, auditor ratification, executive compensation, and other business.

Madrigal Pharmaceuticals' proxy statement highlights a transformational 2024, marked by the FDA approval and successful launch of Rezdiffra, the first-ever medicine for MASH.

Madrigal Pharmaceuticals will hold its annual stockholders meeting on June 25, 2024, to vote on director re-elections, auditor ratification, executive compensation, and a stock plan amendment.

Madrigal Pharmaceuticals highlights a transformational year marked by the FDA approval of Rezdiffra, significant financial milestones, and strategic leadership changes.

Dr. Rebecca Taub, a director at Madrigal Pharmaceuticals, filed an amended Schedule 13D to update her beneficial ownership, now totaling 7.8% of common stock, and disclose recent share transactions.

Dr. Paul A. Friedman, a director at Madrigal Pharmaceuticals, Inc., filed an amended Schedule 13D disclosing a 7.8% beneficial ownership stake and recent stock transactions.

Paulson & Co. Inc. has filed a Schedule 13G reporting beneficial ownership of 6.1% of Madrigal Pharmaceuticals, Inc. common stock.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 8.8% of Madrigal Pharmaceuticals, Inc. common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Madrigal Pharmaceuticals Inc. following an internal realignment.

Janus Henderson Group plc has disclosed an 8.3% beneficial ownership stake in Madrigal Pharmaceuticals, Inc., holding 1,842,690 common shares.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 9.9% in Madrigal Pharmaceuticals, Inc. common stock as of June 30, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of March 31, 2025.